HAE vs. ALGN, MMSI, ICUI, XRAY, QDEL, NEOG, STAA, CERS, OSUR, and ANIK
Should you be buying Haemonetics stock or one of its competitors? The main competitors of Haemonetics include Align Technology (ALGN), Merit Medical Systems (MMSI), ICU Medical (ICUI), DENTSPLY SIRONA (XRAY), QuidelOrtho (QDEL), Neogen (NEOG), STAAR Surgical (STAA), Cerus (CERS), OraSure Technologies (OSUR), and Anika Therapeutics (ANIK). These companies are all part of the "health care supplies" industry.
Haemonetics vs.
Align Technology (NASDAQ:ALGN) and Haemonetics (NYSE:HAE) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, community ranking, profitability, earnings, institutional ownership and risk.
Align Technology currently has a consensus target price of $266.73, indicating a potential upside of 56.56%. Haemonetics has a consensus target price of $101.22, indicating a potential upside of 56.80%. Given Haemonetics' stronger consensus rating and higher probable upside, analysts plainly believe Haemonetics is more favorable than Align Technology.
Align Technology received 391 more outperform votes than Haemonetics when rated by MarketBeat users. Likewise, 69.84% of users gave Align Technology an outperform vote while only 61.60% of users gave Haemonetics an outperform vote.
Align Technology has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.43, suggesting that its stock price is 57% less volatile than the S&P 500.
In the previous week, Align Technology had 9 more articles in the media than Haemonetics. MarketBeat recorded 22 mentions for Align Technology and 13 mentions for Haemonetics. Align Technology's average media sentiment score of 0.91 beat Haemonetics' score of 0.55 indicating that Align Technology is being referred to more favorably in the media.
Align Technology has a net margin of 10.54% compared to Haemonetics' net margin of 9.47%. Haemonetics' return on equity of 23.66% beat Align Technology's return on equity.
88.4% of Align Technology shares are held by institutional investors. Comparatively, 99.7% of Haemonetics shares are held by institutional investors. 0.6% of Align Technology shares are held by insiders. Comparatively, 1.8% of Haemonetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Align Technology has higher revenue and earnings than Haemonetics. Haemonetics is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.
Summary
Align Technology beats Haemonetics on 12 of the 18 factors compared between the two stocks.
Get Haemonetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HAE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Haemonetics Competitors List
Related Companies and Tools
This page (NYSE:HAE) was last updated on 3/25/2025 by MarketBeat.com Staff
Buy HAE Stock Free HAE Stock Alerts